Ezetimibe: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NICE (England) and PHARMAC (New Zealand) recommended or restricted ezetimibe, while CONITEC (Brazil) did not recommend it.
The file has been open for more than a decade: 22.2 years separate the first record, 8 Sep 2003 at SMC (Scotland), from the most recent, 29 Dec 2025 at CONITEC (Brazil).
No assessment is on file from AWMSG (Wales), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for ezetimibe by the agencies that label one in English (NICE, PBAC and SMC).
2 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess ezetimibe, on 8 Sep 2003; CONITEC (Brazil) did not open a file until 29 Aug 2018 — an unusually long tail of 14.9 years between the earliest and latest system to look at it.
3 of the 6 agencies here assessed ezetimibe more than once, HAS (France) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for ezetimibe.
The full ledger for ezetimibe reads 8 other, 4 recommended, 2 not recommended and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 Nov 2019 | Listing renewal (Transparency Committee) | SMR substantial | source |
| CONITEC (Brazil) | 29 Aug 2018 | Tratamento da dislipidemia | not incorporated | source |
| PBAC (Australia) | 2017 | High cholesterol | The PBAC considered the Post- market Review of Ezetimibe Report, stakeholder submissions t… | source |
| NICE (England) | 24 Feb 2016 | NICE TA385 | recommended | source |
| PHARMAC (New Zealand) | 17 Mar 2004 | Hyperlipidemia | PTAC advice: Recommended for funding with no priority · decision reached | source |
10 further decisions for ezetimibe, across 4 agencies, are not shown here. They include the most recent record on file, 29 Dec 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- evolocumab — same ATC class C10A — Lipid modifying agents
- alirocumab — same ATC class C10A — Lipid modifying agents
- rosuvastatin — same ATC class C10A — Lipid modifying agents
- inclisiran — same ATC class C10A — Lipid modifying agents
- evinacumab — same ATC class C10A — Lipid modifying agents
- fenofibrate — same ATC class C10A — Lipid modifying agents
Coverage: 15 decisions for ezetimibe from 6 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class C10A — Lipid modifying agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.